An accurate dissection of peripheral blood enumeration is lacking in primary Sj€ ogren's syndrome (pSS). The purpose of this study was to quantify different leucocyte populations in peripheral blood of patients with pSS. Numbers of specific leucocyte subsets were determined in 86 pSS patients and 74 healthy donors quantifying 21 distinct subtypes by flow cytometry. Subgroups of pSS patients were stratified based on presence of extraglandular manifestations (EGMs) and SSA/SSB autoantibodies. Overall, pSS patients manifested decreased lymphocyte subpopulations compared to healthy donors. Such decreases were more pronounced in SSA/SSB positive patients and patients with EGM. Granulocyte and monocyte subpopulations were increased in pSS patients compared to healthy donors, with the greatest increases in SSA/SSB positive patients. Unsupervised hierarchal clustering based on cell quantities was used to further subgroup the pSS patients into four clusters. One of the clusters characterized by higher concentrations of NKT cells, CD56hi NK cells, CD20 + CD38 À B cells and CD8 + CD38 À T cells was associated with weaker clinical symptoms than the other clusters, possibly marking a milder disease phenotype. In conclusion, our analyses indicate significant alterations in the cellular profiles of peripheral blood leucocytes in patients with pSS and may help to stratify the patients according to disease severity.
Introduction
Sj€ ogren's syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltrates of exocrine glands, notably salivary and lacrimal glands combined with immune-mediated glandular destruction [1] . The hallmarks of the disease are dryness of the mouth (xerostomia) and eyes (keratoconjunctivitis sicca). This dryness and other clinical manifestations result in a significant decrease in life quality of those affected by the disease. Of particular concern is a significantly increased risk of lymphoma development (approximately ninefold) [2] . Sj€ ogren's syndrome can be encountered alone (primary Sj€ ogren's syndrome, pSS) or with other systemic autoimmune diseases (secondary Sj€ ogren's syndrome, sSS) [3, 4] . The prevalence of pSS has been estimated to be 0.05% [5] , with the disease primarily affecting females (female to male ratio of 9:1) with onset between the ages of 40 and 60 [1] . There is no cure for the disease, with disease management based on symptom relief and the treatment of complications. The inability to develop an effective treatment or cure of pSS can be linked to a number of factors. First, the disease aetiology is poorly understood and highly complex; genetic, epigenetic, environmental, hormonal and neuropsychological factors are thought to play a role [6] . Second, studying the disease is notably difficult. This is in part due to diagnostic delay with the previous classification criteria from the American European Consensus Group (AECG) requiring the onset of clinical signs or symptoms [7] , which may take years after onset. In particular, this becomes evident because autoantibodies are detectable up to two decades before symptom onset in pSS [8, 9] . This issue might be reduced by the 2016 classification criteria approved by the American College of Rheumatology (ACR) Board of Directors and the European League Against Rheumatism (EULAR) Executive Committee not requiring objective symptoms [10, 11] . Additionally, patients with SS are very heterogeneous and present symptoms characteristic of multiple disease phenotypes, medication side effects and general ageing, further delaying diagnosis. Because of these factors, clinicians and researchers alike urgently need additional reliable biomarkers for SS diagnosis and patient stratification. Identification of such biomarkers should allow for the evaluation of potential risk of further complications such as lymphoma development [12] , as well as improve therapeutic clinical trials design.
Peripheral blood provides an ideal source for biomarker discovery due to its routine clinical collection. Peripheral blood acts as a traffic route and mediator for immune cells including granulocytes, monocytes, natural killer (NK) cells, T cells, B cells and dendritic cells. The cells continuously traffic between lymphoid and non-lymphoid organs and sites of inflammation, monitoring and responding to a myriad of threats including viruses, bacteria and cancerous cells as well as regulating immune response. The examination of the makeup of the cellular components of peripheral blood may thereby provide a snapshot into the state of the immune system. Such examinations may indicate ongoing immune responses as well as dysregulations of immune homoeostasis prevalent in autoimmune diseases. Quantitative and qualitative modifications of immune cell subsets have been shown in individuals suffering from various infections and autoimmune diseases such as systemic lupus erythematosus (SLE) [13] , rheumatoid arthritis (RA) [14] , and hepatitis B [15] . Moreover, also patients with pSS have been reported to have changes in cell composition with decreases in CD56 + NK cells [16] and CD4 + T cells [17] , and increases in double negative (CD4 À /CD8 À ) T cells [18] and CD20 + B cells [19] . Additionally, these changes have been linked to other manifestations; for example, decreases in CD4 + T cells have been associated with extraglandular manifestations (EGMs) [17] and anti-SSA antibodies [20] . However, these studies have often been hampered by extensive processing of the sample prior to analysis, and estimations of cell numbers were often made in reference to their parental population (such as CD4 + T cells to CD3 + T cells) or grandparent population (CD4 + T cells to lymphocytes). Such estimates thereby do not take into account if a patient is for example lymphopenic.
The purpose of this study was to investigate the quantitative composition of leucocyte subsets in peripheral blood from pSS patients with different clinical manifestations. Flow cytometry of whole blood was used to determine frequency per ll blood of cell subsets identified by expressed immune markers. Direct quantification in whole blood eliminates processing steps such as density gradient centrifugation that may affect the composition and provides a more accurate description of the cellular makeup. Quantities of each cellular subtype in peripheral blood from patients with pSS were compared to age-and gender-matched healthy controls. We next dissected the response further by comparing absolute counts of healthy donors to subgroups of patients based on EGM and presence of SSA/SSB autoantibodies. Unsupervised hierarchical clustering of patients based on cell concentrations was used to group patients and see whether these grouping reflected clinical measures.
Materials and methods
Blood sampling. Peripheral venous blood was collected from each donor in Lithium-heparin-containing vacutainer tubes (BD diagnostics, San Jose, CA, USA). Blood samples from 86 pSS patients were collected at the Department of Rheumatology, Haukeland University Hospital, Bergen, Norway. All patients fulfilled the pSS American European Consensus group criteria (AECC) [7] . The control group consisted of 74 gender-and age-matched healthy controls recruited from the same geographical area as the patients at the blood bank at Haukeland University Hospital, Bergen, Norway. An overview of patients and controls used in this study is shown in Table 1 . The study was approved by the regional ethical committee (#2009/686). All participants provided written informed consent.
Routine laboratory assays. Measurements and identification of anti-Ro/SSA, anti-La/SSB, rheumatoid factor (RF), immunoglobulin levels (IgG, IgA and IgM), other antinuclear antibodies (ANA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement component 3 (C3) and 4 (C4), focus score, EGMs at time of blood sampling, Schirmer's test, stimulated and unstimulated saliva were obtained as part of routine clinical patient care. Extraglandular manifestations were defined as disease features outside surface exocrine glands (except low white blood cell counts) including Raynaud's phenomenon (n = 8), arthralgias (n = 7), arthritis and polyarthritis (n = 9), neuropathy (n = 5), mucosa-associated lymphoid tissue lymphomas (n = 1), Discoid Lupus (n = 2), vasculitis and purpura (n = 4) and pulmonary infiltrates (n = 2).
Monoclonal antibodies used for flow cytometry. A general phenotyping panel was used to identify the major leucocyte subsets in peripheral blood. The following monoclonal antibodies were used as follows: CD45 Qdot 605 (clone HI30; Molecular Probes, Eugene, OR, USA), CD3 Horizon V500 (clone UCHT1), CD56 PE-Cy7 (clone NCAM16.2), CD4 Pacific blue (clone RPA-T4; all BD Biosciences, San Jose, CA, USA), CD20 Alexa Fluor 647 (clone 2H7), CD8 PerCP-Cy5.5 (clone RPA-T8; both Biolegends, San Diego, CA, USA), CD14 FITC (clone MEM-18; Immunotools, Friesoythe, Germany), CD38 PE (clone HB7; eBiosciences, San Diego, CA, USA) and CD16 APC-Cy7 (clone 3G8; BD Pharmingen, San Jose, CA, USA).
Quantification of absolute cell counts. TruCount TM tubes (BD Biosciences) were used to determine absolute counts of leucocyte subtypes in peripheral blood. The tubes were used according to manufacturer's recommendations. Fifty microlitres of whole blood was transferred to a TruCount TM bead gate for each sample. Initial analyses were performed using FLOWJO software (Treestar, Ashland, OR, USA). The gates defining negative and positive leucocyte subpopulations for each surface marker were set using colour density bi-exponential displays, fluorescence minus one (FMO) controls and back gating. An overview of the gating strategy is shown in Fig. 1 . Cells per ll calculations were based on cell count, bead count and total number of beads in the tube.
Statistical analysis. Unpaired Mann-Whitney test was used in the analysis of differences between groups for continuous data. For univariate comparisons of categorical data, Fisher's exact test was used (both tests using GRAPHPAD, Graphpad Software, Inc, La Jolla, CA, USA). Differences were considered statistically significant when P ≤ 0.05. As the analysis was exploratory, no corrections for multiple comparisons were made. Principal component analysis (PCA) and unsupervised hierarchical clustering were performed using R statistics version 3.3.1. and the R package FACTOMINER [21] . Variables used in PCA were log-transformed prior to analysis, and all variables were centred and standardized by dividing by their respective standard deviation. Hierarchical clustering was performed on natural logarithm (ln)-transformed data. Data were shifted to a mean of 0 and SD of 1 before using Ward's linkage with Euclidean distances, and a four cluster solution was used for subsequent analysis.
Results

Absolute cell counts differ between pSS patients and healthy controls
Absolute counts were determined for the leucocyte subsets within peripheral blood for pSS patients and age-and gender-matched healthy donor samples. Significant differences were observed between pSS patients and healthy controls (Fig. 2 , Table S1 ). Monocytes and granulocytes tended to be increased in pSS patients, with a significant 21 (25) a Anti-CCP (%) 2 (2) Anti-RNP (%) 6 (7) Other (%)
26 ( cells. The majority of these changes were not a consequence of prescribed medication, as significant differences remained in most cellular subsets when excluding patients using corticosteroids or DMARDs (data not shown). Only granulocytes, CD56 hi CD16 À NK and CD20 + B cells were no longer significant following exclusion of patients using corticosteroids or DMARDs, but the general relationship between the pSS patient and healthy donor samples remained unchanged. Individuals using corticosteroids or DMARDs tended to have more pronounced decreases in lymphocyte concentrations in peripheral blood than patients not using any medication ( Figure S1 ), but only pSS patients using DMARDs had significantly reduced lymphocyte counts compared to non-medicated pSS patients. Whether this is the result of the medication or worsening disease symptoms leading to increased use of medication is unclear. No differences were found in Figure 1 Representative gating strategy used in the identification of cell populations. Beads, cells and debris were separated using their forward (FSC) and side scatter (SSC) properties. Leucocytes were then identified by their CD45 expression, with granulocytes, monocytes and lymphocytes identified based on scatter properties and CD45 expression. Granulocytes were further identified based on CD16 expression. Monocytes were subtyped according to their CD14 and CD16 expression as nonclassical (CD14 monocyte and granulocyte concentrations between nonmedicated pSS patients and patients using corticosteroids or DMARDs. We next dissected the response further by comparing absolute counts of healthy donors to subgroups of patients based on EGM and presence of SSA/SSB autoantibodies (Fig. 2 , Tables S2 and S3).
Absolute cell counts differ between EGMÀ and EGM+ patients EGM+ patients showed significant increases in granulocytes compared to healthy donors (Fig. 2 , Tables S2 and  S3 ). No differences in monocyte and monocyte subtype numbers were observed in EGM+ and EGMÀ patients compared to healthy donors. Reductions in lymphocytes Figure 2 Absolute cell counts differ significantly between pSS patients, healthy controls and subgroups of patients. Heat map of relative median quantities of leucocyte subsets in pSS patients (n = 86) divided into patients with or without extraglandular manifestations (EGM+; n = 32/EGMÀ; n = 54) and autoantibody positive (SSA/SSB+; n = 62) and negative (SSA/SSBÀ; n = 24) patients, compared to healthy controls (n = 74). Statistically significant differences are indicated by asterisks with black asterisks for comparisons to healthy donors, and red asterisks for significant differences between patient subgroups. Statistical analysis of differences was conducted using an unpaired Mann-Whitney test, significant P values are denoted as *˂0.05, **˂0.01, ***˂0.001, ****˂0.0001. Ctrl, healthy donor; pSS, primary Sj€ ogren's syndrome patient donor; EGM, extraglandular manifestation; SSA, antiSj€ ogren's syndrome-related antigen A; SSB, anti-Sj€ ogren's syndrome-related antigen B.
Ó 2017 The Foundation for the Scandinavian Journal of Immunology .......................................................................................................................................................... À B cells were significantly reduced in patients with EGM compared to those without. The cellular deficiencies were thus more pronounced in patients with more severe disease manifestations. When excluding medicated patients, comparisons of cell quantities between EGM+ (n = 12) and EGMÀ patients (n = 34) showed no significant differences in the subgroups. Although EGM+ patients tended towards lower counts of lymphocyte subtypes compared to EGMÀ patients, with exception of CD8 + CD38 + T cell subset which was increased. Further, dissection of the cohort by treatment and patients with or without EGM revealed a nonsignificant trend of reduced lymphocyte counts in EGM+ patients, and a trend of reduced T cells through reductions in the CD4 + subsets ( Figure S2A ), but this did not reach statistical significance. In addition, medicated patients tended to have slight reductions in cell counts compared to non-medicated patients.
Absolute cell counts differ between autoantibody SSA/SSB+ and SSA/SSBÀ patients Increased monocytes and granulocytes counts in peripheral blood were observed in SSA and/or SSB+ patients compared to healthy donors (Fig. 2 patients. However, following exclusion of medicated patients the differences between the subgroups lost statistical significance. Further dissection of the cohort by treatment (nonmedicated, corticosteroids and DMARDs) and autoantibody positivity indicated that these cell subsets were more strongly reduced in SSA+ or SSB+ patients than SSAÀSSBÀ patients irrespective of treatment, although the differences were not significant ( Figure S2B ).
PCA indicates shifts in cell concentrations in pSS
Principal component analysis showed a vertical and left skewed distribution of pSS samples along Dim1 and Dim2 (Fig. 3A) , indicating that the variables contributing to Dim1 (principal component 1) and Dim2 (principal component 2) helped distinguish patient samples from healthy donor samples. When we subgrouped the pSS patients into either EGM+/EGMÀ, or SSA+ or SSB+/SSA-SSBÀ, EGMÀ (Fig. 3B) and SSAÀSSBÀ (Fig. 3C ) patients grouped closer to healthy donors compared to EGM+ and SSA+ or SSB+ pSS samples. Dim1 explained 26.2% of the variability while Dim2 explained 16.5%. Positive movement along Dim1 was dominated by changes in lymphocyte cell subsets, while granulocytes and monocyte subsets dominated Dim2.
Hierarchical clustering of pSS patients based on absolute cell concentrations
We next used unsupervised hierarchical clustering to subgroup patients based on absolute cell counts per ll blood (Fig. 4) 
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+ cells. Cluster 4 had the lowest levels of granulocytes and monocytes, with moderate levels of lymphocyte subsets compared to the other clusters.
The identified clusters were then further examined for association to clinical manifestations (Fig. 5) . Clusters 2, 3 and 4 displayed no significant associations, while cluster 1 showed manifestations associated with less severe disease: significantly lower levels of IgG, lowest levels of IgM, higher levels of complement proteins C3 and C4 and highest tear production (Schirmer's test). No significant differences were found between patient clusters with regards to IgA, UWS, SWS and focus scores.
Examination of categorical differences showed no significant differences between the groups in focus score ˃1, although cluster 1 showed a lower frequency of patients with a focus score of 1 or less (19%) than clusters 2 (44%), 3 (50%) and 4 (37%). Cluster 1 showed lower frequencies of SSA+ patients (53%) than clusters 2 (87%), 3 (76%) and 4 (64%), with significantly lower frequencies in comparison with cluster 2. Similarly cluster 1 exhibited lower frequencies of SSB+ patients (12%), with significantly reduced frequencies compared to cluster 2 (48%) and cluster 3 (48%). Although cluster 1 showed lower frequencies of EGM (47%) than clusters 2 (65%), 3 (67%) and 4 (56%), this did not reach statistical significance. EGMs were further subdivided into constitutional and musculoskeletal (including arthralgia and arthritis), and Raynaud's phenomenon type EGM and other EGM (neuropathy, mucosa-associated lymphoid tissue lymphomas, discord lupus, vasculitis, purpura and pulmonary infiltrates). Little difference was shown between clusters for constitutional and musculoskeletal, and ............................................................................................................................................................... Raynaud's phenomenon type EGM. Patients in cluster 1 displayed other EGM at lower levels (0%) than clusters 2 (14%), 3 (33%) and 4 (25%); however, only comparisons between cluster 1 and 3 were significant. The use of medication and corticosteroids was found to be highest in cluster 3, while corticosteroids use was more common in cluster 2 and 3, with no use in cluster 1. Patients using biologics (n = 3) were restricted to cluster 3.
Discussion
We here investigated absolute numbers of 21 leucocyte subsets in the peripheral blood of pSS patients subgrouped according to clinical manifestations, compared to healthy controls, in order to define better biomarkers to stratify pSS patients. We found significant differences between patients and healthy controls, as well as within the pSS patient group, depending on presence or absence of EGM and autoantibodies against SSA and/or SSB. Changes in cell populations could arise due to increased apoptosis or migration from peripheral blood because of disease aetiology and pathological mechanisms. Hence monitoring these changes might inform on the clinical progression of the disease, or allow for identification of disease subtypes. Reductions of different lymphocyte subclass concentrations in peripheral blood of pSS patients have previously been reported [16, 17, 22, 23] , with decreases also associated with presence of SSA or SSB autoantibodies [22, 23] corresponding well to our observations validating the methodological approach. By omitting isolation of PBMC and using full blood instead, our approach reduced handling time and manipulation of the blood samples, thus increasing the robustness of the results.
In our study, losses of CD8 + and CD20 + were shown to be specific for their CD38 À subtypes, while CD4 + T cell declines were observed in both CD38
À and CD38 ............................................................................................................................................................... 
patients, CD8
+ CD38 + T cells were increased in numbers. Although not significant, this trend was stronger in EGM positive patients than negative patients. Mingueneau et al. [23] noted that although both CD4 + and CD8 + T cells showed signs of activation determined by HLA-DR expression, only CD8 + T cells showed activation in exocrine gland tissue and that CD8 + T cells were strongly associated with clinical features. They speculated that CD8 + T cells play a key cellular role in mediating tissue destruction. It is possible that their activation and movement to affected locations is involved in tissue destruction and contributes to the development of EGM.
The current study indicates that the degree of reduced cell numbers is dependent on cell subtype and correlates with clinical manifestations. This indicates that the cause of lymphopenia reported in some patients [24] is directed more strongly at different cell types depending on disease progression and/or the development of comorbidities. In pSS, the majority of infiltrating mononuclear cells at minor salivary gland lesions are T (mainly CD4 + ) and B cells (more than 90%) [25, 26] . T cells have been previously shown to be decreased, while B cells increase with infiltration grade in salivary gland lesions [25] . CD4 + T cells followed the same trend as T cells, while CD8 + T cells remained unchanged [25] . NK cells have also been reported to be present in lesions, and their percentage correlated with the grade of the lesion [25] . B-cell accumulation in salivary glands has been associated with elevated levels of anti-SSA and anti-SSB antibodies and IgG [27] . It is reasonable to hypothesize that losses in peripheral blood cell populations may contribute to relative cell increases in the salivary glands, or alternative the same processes are contributing to both features. Future research will have to focus on linking the two observations. Granulocytes were increased in patients with SSA and/ or SSB autoantibodies. Granulocytes are composed mainly of neutrophils of which little is known regarding their role in the pathogenesis of pSS. Neutrophils have a short lifespan in circulation (approximately 5 days) [28] , with homoeostasis maintained by their continuous release from the bone marrow [29] . Therefore, their increased occurrence in circulation may result from increased release from bone marrow possibly due to disease associated inflammatory processes. Alternatively, neutrophils in pSS have been described to have decreased surface adherence compared to controls [30] . This property may have affected the number of cells liberated during the venous puncture or alternatively decreased adherence to tubes during processing. However, the increase was limited to SSA/SSB positive patients; therefore, increases in granulocytes may also be associated with antibody-mediated phagocytosis or release of autoantigens through cell cytotoxicity.
Unsupervised hierarchical clustering was used to stratify patients and examine whether the groupings could be associated with clinical manifestations of the disease. Little differences in clinical measures were seen between cohorts 2, 3 and 4, while cohort 1 displayed lower measurements associated with disease activity. The cohort was characterized by increased concentrations of NKT cells, CD56
hi NK cells, CD20 + CD38 À B cells and CD8 + CD38 À T cells.
Changes in these cell populations may indicate more severe disease suggesting that regular analysis of these cell types could be beneficial in stratification or monitoring of patients. Further investigations are required to discern whether the losses of these cell subtypes are a consequence or a driver of the described manifestations, and whether their loss is predictive of development of future complications associated with the disease. The presented study should be interpreted with care due to the use of medication within the pSS cohort. Differences in cell concentrations in peripheral blood between pSS patients and healthy donors were similar when including or excluding patients using medication, indicating the reductions to be associated with the disease and not medication. However, the strength of these relationships differed with comparisons between EGM+ and EGMÀ patients, and SSA+ or SSB+ and SSAÀSSBÀ patients following exclusions of medicated patients and dissection of the cohort based on medication. A number of factors may cause these differences. For one, sample size was greatly reduced when subgrouping following exclusion of medicated patients (SSA+ or SSB+, n = 31; SSAÀSSBÀ, n = 15; EGM+, n = 12 and EGMÀ, n = 34). Second, exclusion of medicated patients likely bias the sample by removing patients with more severe disease. Third, pSS patients often present with a number of comorbidities, these have not been included in the analysis. And fourth, medication likely has an analogous effect on cell concentrations to disease-associated changes. The corticosteroid prednisolone has been shown to cause leucocytosis in patients with leucocytosis-associated diseases through increases in granulocytes, monocytes and lymphopenia, over a 21-day period [31] . Additionally, decreases in lymphocyte and monocyte counts have been observed in individuals with fever of unknown origin following administration of prednisolone [32] . Little evidence exists in published literature for an association of hydroxychloroquine with increased monocyte or granulocyte counts or lymphopenia. However, hydroxychloroquine has been shown to induce apoptosis in in vitro cultures of lymphocytes [33] . Nevertheless, little effect was seen in monocyte and granulocyte concentrations when comparing pSS patients subdivided by medication use. Although greater lymphocyte reductions were associated with the use of different medications, controlling for this indicated that presence of EGM or autoantibodies was associated with increased reductions.
In conclusion, pSS patients had most noticeable decreases in CD4 + and CD8 + T cells lacking CD38 expression, and CD20 + /CD38 À B cells in peripheral blood compared to age-and gender-matched healthy controls, with increases in monocytes and granulocytes. Moreover, the absolute cell count variations were correlated to clinical parameters within the group of pSS patients, enabling further subgrouping. This might be of clinical relevance regarding treatment and monitoring of the patients.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 Concentrations of granulocytes, monocytes and lymphocytes (cells/µl) in peripheral blood from healthy donors (Ctrl), and pSS patients grouped by medication use (no medication, corticosteroids and DMARDs). Patients using biologics (n = 3) are excluded. Median and 25-75 percentiles are shown. Statistical analysis of differences was conducted using an unpaired Mann-Whitney test, significant P values are denoted as *˂0.05, **˂0.01, ***˂0.001, ****˂0.0001. Figure S2 Concentrations of lymphocyte cell subsets (cells/µl) in peripheral blood from healthy donors (Ctrl), pSS patients group by EGM (A) or autoantibodies (SSA+ or SSB+, B) and further dissected by medication use (no medication, corticosteroids and DMARDs). Patients using biologics (n = 3) are excluded. Median and 25-75 percentiles are shown and the key is given to the right of the figure. Statistical analysis of differences was conducted using an unpaired Mann-Whitney test, significant P values are denoted as *˂0.05, **˂0.01, ***˂0.001, ****˂0.0001. Table S1 Comparison of absolute counts of leucocyte subsets (median and 95% confidence interval of median, cells/µl) in peripheral blood from 74 healthy adults and 86 pSS patients. 
